Plant extracellular vesicle loaded with amiRNA and application of plant extracellular vesicle in tumor inhibition

By introducing EXO motifs amiRNA into plant extracellular vesicles, targeted inhibition of c-myc mRNA is achieved, solving the problems of low efficiency and strong non-targeting of traditional Chinese medicine loading in the prior art, and significantly inhibiting tumor cells. Proliferation and apoptosis have important tumor therapeutic value.

CN118979015APending Publication Date: 2024-11-19NANJING NORMAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411188584.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-28
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The prior art knows less about the mechanism of active loading of small RNAs (such as amiRNAs) in plant extracellular vesicles, and existing methods may destroy vesicle structure or lead to low drug loading efficiency, strong non-targeting, and difficult to effectively inhibit tumor growth. .

Method used

By introducing specific EXO motifs into the nucleotide sequence of amiRNA, it can be actively loaded into plant extracellular vesicles, improving the loading and efficiency of amiRNA, and targeting c-myc mRNA to inhibit the proliferation and apoptosis of tumor cells. .

Benefits of technology

It significantly improves the load of amiRNA and tumor suppression effect in plant extracellular vesicles, can effectively inhibit the expression of c-myc protein, promote tumor cell apoptosis, and has important tumor therapeutic significance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118979015A_ABST
    Figure CN118979015A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of anti-tumor reagents, in particular to a plant extracellular vesicle loaded with amiRNA and application of the plant extracellular vesicle in tumor inhibition. The plant extracellular vesicle is prepared by the following method: modifying the amiRNA, and loading the modified amiRNA into the plant extracellular vesicle, the modification comprises the following steps: editing a nucleotide sequence of the amiRNA in a mode of exchange or mutation, so that the sequence contains at least one EXO motifs; and the EXO motifs comprises one or more of AACG (advanced access control group), CAUAG (advanced access control group) or GGGUCC (general gateway universal joint carrier). According to the invention, several EXO motifs are found through researches, and the EXO motifs can promote plant extracellular vesicles to actively load amiRNA. Based on the method, the invention further provides the plant extracellular vesicles targeting the c-mys protein, and the plant extracellular vesicles can remarkably inhibit tumor growth and promote tumor cell apoptosis and have important application value in the field of tumor treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of anti-tumor agents, and in particular to a plant extracellular vesicle loaded with amiRNA and an application thereof in inhibiting tumors. Background Art

[0002] Extracellular vesicles (EVs) refer to vesicles formed by direct budding and rupture of the cell membrane or by the fusion and release of the intracellular multivesicular body membrane and the plasma membrane. According to their physical properties and biogenesis pathways, they are mainly divided into two categories: exosomes and microvesicles. During programmed cell death, apoptotic bodies formed by cell budding are also classified as a type of extracellular vesicles. Exosomes are essentially intraluminal vesicles formed by the inward depression and rupture of the multivesicular body (MVB) membrane. When the multivesicular body membrane fuses with the plasma membrane, these intraluminal vesicles are released into the extracellular space in the form of exosomes, with a diameter of between 50-150nm. Microvesicles are formed by the rupture and shedding of the outward protrusions of the cell membrane, with a diameter ranging from 200nm to 1μm. EVs can selectively encapsulate intracellular nucleic acids, proteins, lipids and other metabolites, and play an important role in maintaining body homeostasis, resisting pathogen invasion, and regulating tumor cell growth. At present, animal EVs have shown great potential in clinical applications. By manipulating EVs in vitro, they can be used as carriers for loading specific siRNA, miRNA, proteins and small molecule drugs for the treatment of specific diseases. Plant cells can also secrete extracellular vesicles. Currently, three subclasses have been identified in Arabidopsis based on the different EVs membrane proteins: TET8 (Tetraspanin 8) positive vesicles, PEN1 (Penetration 1) positive vesicles and Exo70E2 positive vesicles. TET8 positive vesicles are plant exosomes, just like the biogenesis pathway of animal exosomes. Multiple plant EVs omics data show that EVs carry some proteins, lipids and nucleic acids involved in specific biological processes.

[0003] At present, animal EVs used in disease treatment and medical aesthetic research are mostly derived from tumor cells, stem cells, T-cells and endothelial cells. EVs derived from tumor cells loaded with tumor-related biomarkers may induce normal cells to become cancerous and are not suitable for disease treatment. EVs derived from stem cells, especially mesenchymal stem cells (MSCs), have great potential in disease treatment, but mesenchymal cells are mainly derived from placenta, umbilical cord tissue and bone marrow, which are not easy to obtain. In addition, disease treatment research also mentions plant exosome-like nanoparticles (PELNs), which are nanoparticles with a similar morphology and size to exosomes released by MVBs collected from plant tissue homogenates by ultracentrifugation. It is not all extracellular vesicles secreted by plants under natural physiological conditions, but also includes vesicles in cells during tissue fragmentation and vesicles similar in size to exosomes derived from cell membranes and endomembrane systems. During tissue fragmentation, functional molecules such as RNA, DNA, and proteins endogenous to plants can be loaded into nanoparticles. It has the characteristics of high extraction yield, wide sources, low immunogenicity, low cytotoxicity to healthy tissues, and excellent biocompatibility. PELNs extracted from medicinal plants have been shown to have significant regulatory effects in antiviral, anti-tumor, immune regulation, and tissue repair because they are loaded with natural active substances from medicinal plants during tissue fragmentation. However, compared with EVs naturally released by cells, its composition is complex and heterogeneous.

[0004] miRNA is an information molecule transported by EVs that can regulate the expression of target genes. Compared with miRNAs synthesized in animal cells and artificially synthesized by chemical methods, the 3' end of miRNAs synthesized in plant cells has methylation modification. Huaenhancer1 (HEN1) catalyzes the methylation reaction at the 2'-O position of the 3' terminal nucleotide of the miRNA / miRNA* duplex. Methylation can improve the stability of miRNA. The function of miRNA depends on the complementarity with mRNA, and there is no boundary in plants and animals. At present, studies have reported that endogenous plant miRNAs are absorbed by the human body in the form of vesicles and target pathogenic genes. miR159 is a miRNA that can inhibit breast cancer in plants. Its content in human serum is negatively correlated with the incidence of breast cancer. It is mainly present in EVs and can bind to the 3'UTR region of the oncogene TCF7 mRNA, reduce cell proliferation by degrading TCF7 mRNA, and achieve the effect of inhibiting tumor growth. During the treatment of brain tumors, grapefruit-derived PELNs carrying miR17 can quickly enter the brain and be absorbed by tumor cells through nasal administration, playing a role in slowing the growth of brain tumors.

[0005] EVs drug loading is divided into loading of endogenous and exogenous drugs. Endogenous loading is the loading of proteins, nucleic acids and small molecules that can be naturally produced in cells. Endogenous loading is divided into passive loading and active loading. Passive loading is based on the overexpression of the required molecules in cells and relies on the passive capture of these molecules in EVs; active loading is based on the classification and recognition mechanism of cells, and can actively and selectively load drugs. Exogenous loading mostly adopts passive loading, usually incubating drugs or molecules directly with EVs or donor cells of EVs. Hydrophobic small molecules can passively enter the lipid bilayer of exosomes through co-incubation, and the concentration of hydrophobic drugs plays a decisive role in drug loading efficiency. However, due to its non-targeted nature, it may lead to low EV yield and limited drug loading. Common drug loading methods to improve drug loading efficiency include electroporation, ultrasound, extrusion, freeze-thaw cycles, etc. There are also studies on loading EVs by overexpressing miRNA in cells, but these methods have low loading capacity and may destroy the structure of vesicles, affecting the absorption of receptor cells. In addition, membrane permeability agents and surfactants (such as saponin) can interact with cholesterol in the EVs membrane to form pores to increase drug loading efficiency, but the hemolytic effect of saponin may limit its application. In summary, the existing technology has little understanding of the mechanism of active loading of sRNA in EVs, and the only two examples are studies on animal cells. Summary of the invention

[0006] In order to solve the problems existing in the prior art, the present invention provides a plant extracellular vesicle loaded with amiRNA and its application in tumor inhibition. By introducing EXO motifs into amiRNA, the plant extracellular vesicle can actively load the amiRNA, thereby increasing the level of the amiRNA in the plant extracellular vesicle.

[0007] In a first aspect, the present invention provides a method for loading plant extracellular vesicles with amiRNA, comprising: The amiRNA is modified and loaded into the plant extracellular vesicle after modification; The modification includes: editing the nucleotide sequence of the amiRNA by substitution or mutation so that the sequence contains at least one EXO motifs; The EXO motifs include: one or more of AACG, CAUAG or GGGUCC.

[0008] Furthermore, the length of the nucleotide sequence of the amiRNA is 16 to 26 nt, preferably 18 to 24 nt.

[0009] In a second aspect, the present invention provides a plant extracellular vesicle, which is prepared by the plant extracellular vesicle loading amiRNA method.

[0010] Furthermore, the nucleotide sequence of the c-myc mRNA includes: a nucleotide sequence as shown in SEQ ID NO.1 (wild-type sequence of mouse c-myc mRNA) or SEQ ID NO.2 (wild-type sequence of human c-myc mRNA).

[0011] Furthermore, after modification, the amiRNA in the plant extracellular vesicles includes any one or more nucleotide sequences shown in SEQ ID NO.3-7.

[0012] Furthermore, the plant is tobacco, preferably Nicotiana benthamiana.

[0013] c-myc is a transcription factor encoded by the proto-oncogene MYC. It is located downstream of a variety of cell proliferation and growth signaling pathways. Its function requires the formation of a dimer with Max and binding to the target DNA sequence or E-box (5'-GANNTG-3') to regulate the transcription of genes related to cell growth and proliferation. In normal cells, c-myc is strictly negatively regulated and is at a low expression level. When due to chromosomal translocation, gene amplification, loss of upstream regulator APC, and abnormal functions of tumor suppressor proteins such as p53 and Arf, c-myc is overexpressed, promoting the transcription of related genes and inducing cell carcinogenesis. Studies have shown that c-myc is dysregulated in more than 70% of tumors. It is an intrinsically disordered protein. The single c-myc protein does not have a stable conformation and a site suitable for small molecule binding. It is a representative target for difficult-to-drug drugs. At present, no drugs that directly act on c-myc protein have been developed. In clinical studies, alternative methods are often used to indirectly target c-myc. Some small molecule inhibitors or peptides are used to interfere with the dimerization of c-myc and max, target the downstream genes regulated by c-myc, downregulate the expression level of c-myc, etc.

[0014] Based on the aforementioned method, the present invention incubated plant extracellular vesicles containing amiR-myc containing EXO motif with cancer cells, and unexpectedly found that amiR-myc targeting the wild-type sequence of mouse c-myc mRNA can inhibit the proliferation of human cancer cells and promote apoptosis of cancer cells after modification (introduction of EXO motif).

[0015] In a third aspect, the present invention provides the use of the plant extracellular vesicles in inhibiting tumors.

[0016] The present invention further provides the use of the plant extracellular vesicles in preparing a drug for inhibiting tumors.

[0017] Furthermore, the tumor inhibition includes any one or more of the following: i) reduce the expression level of c-myc protein; ii) inhibiting tumor growth; iii) Promote tumor cell apoptosis.

[0018] The present invention has the following beneficial effects: The present invention studies the mechanism of active loading of sRNA in plant EVs and identifies several EXO motifs, including "AACG", "CAUAG" and "GGGUCC", etc. These EXO motifs can promote the loading of amiRNA into plant EVs. Based on this discovery, the present invention further provides plant EVs loaded with amiRNA targeting c-myc, which has a significant inhibitory effect on tumors, can effectively inhibit tumor growth, and promote tumor cell apoptosis, which is of great significance in the field of tumor treatment. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] In order to more clearly illustrate the technical solutions in the present invention or the prior art, the following briefly introduces the drawings required for use in the embodiments or the description of the prior art. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0020] Figure 1 It is a short nucleotide motif map that is specifically enriched in EVs when comparing the sequences of 21nt, 21-24nt and 18-24nt sRNAs in EVs and leaf tissues obtained by screening provided in Example 1 of the present invention.

[0021] Figure 2 Schematic diagram of introducing EXO motifs into miRNA provided in Example 1 of the present invention; wherein A is the sequence of nb-miR156I and the sequence of the nb-miR156I mutant containing CAUAG and GGGUCC motifs; B is the ratio of the relative expression of nb-miR156I and the nb-miR156I mutant containing CAUAG and GGGUCC motifs in EVs and leaf tissues; C is the sequence of nb-miR408a containing CCCUG motif and two sequences of nb-miR408a mutants without CCCUG motif; D is the ratio of the relative expression of nb-miR408a and the nb-miR408a mutant without CCCUG motif in EVs and leaf tissues; in the figure, U6 snRNA is used as the internal reference of total RNA in EVs and leaf tissues. Data are presented as mean ± SEM, * represents p <0.0332, ** represents p <0.0021, **** represents p <0.0001.

[0022] Figure 3 Schematic diagram of introducing EXO motifs into amiR-myc sequence provided in Example 1 of the present invention; wherein A is a schematic diagram of 5 designed amiRNAs (amiR-myc) containing EXO motifs; B is the sequence of each of the 5 amiR-myc and the motif contained; C is the relative content of the 5 amiR-myc and the empty vector in EVs; D is the relative content of the 5 amiR-myc in EVs; in the figure, U6 snRNA is used to standardize the RNA amount, and the data are presented as mean ± SEM.

[0023] Figure 4 It is a schematic diagram of the construction of the c-myc amiRNA targeting expression vector provided in Example 1 of the present invention; wherein A, B, I, II, III, and IV represent primers; I and B amplify the 3' end fragment of the miRNA hairpin precursor, III and II amplify the middle stem-loop fragment of the miRNA hairpin precursor, and A and IV amplify the 5' end fragment of the miRNA hairpin precursor.

[0024] Figure 5 is a diagram showing the inhibitory effect of plant extracellular vesicles loaded with amiR-myc-CAUAG-ORF-2 or amiR-myc-GGGUCC-5'UTR on tumors provided in Example 1 of the present invention; wherein A is a schematic diagram showing the inhibitory efficiency of different numbers of plant extracellular vesicles on HCT116 cells; B is a diagram showing the inhibitory effect of 2.5×10 11 Statistical results of cell apoptosis after EVs loaded with amiR-myc-GGGUCC-5'UTR were incubated with HCT116 and ARP1 cells for 48 h; C is 2.5×10 11 Schematic diagram of the expression of c-myc protein in cells after EVs loaded with amiR-myc-GGGUCC-5'UTR were incubated with HCT116 and ARP1 cells for 48 h; *** in the figure represents p <0.0002.

[0025] Figure 6: This is a diagram of the in vitro tumor inhibition effect of plant EVs loaded with amiR-myc provided in Example 1 of the present invention; wherein A is the status of CDX model mice injected with empty EVs and EVs loaded with amiR-myc-GGGUCC-5'UTR on the 28th day; B is the tumor tissue block on the 28th day; C is a weight comparison diagram of tumor tissue blocks taken out of the empty group and the EVs group loaded with amiR-myc-GGGUCC-5'UTR; D is a tumor growth curve diagram drawn by monitoring the tumor volume during tumor growth; E is a diagram of PKH26-labeled plant EVs localized to tumor tissue under a laser scanning confocal microscope; F is a diagram of c-myc expression in tumor tissue detected by immunohistochemistry, showing cells observed under a 40x microscope, scale: 1000μm; * in the figure represents p <0.05. DETAILED DESCRIPTION

[0026] In order to make the purpose, technical solution and advantages of the present invention clearer, the technical solution of the present invention will be clearly and completely described below in conjunction with the drawings of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0027] Example 1

[0028] The present invention provides a plant extracellular vesicle (EVs) targeting the proto-oncogene c-myc, and verifies its function. The specific process is as follows: 1. Plant extracellular vesicle sRNAs specific loading motifs EXO motifs

[0029] The present invention performs quality control on the original sequencing data of Nicotiana benthamiana EVs and leaf tissue sRNAs and performs sequence alignment with the Nicotiana benthamiana reference genome (v1.0.1), retaining the reads aligned to the reference genome. HOMER (Hypergeometric Optimization of Motif EnRichment, v4.11) is used to identify short nucleotide motifs with high abundance in EVs sRNAs. Specifically, HOMER runs the RNA motifs identification mode, and the motif length is set to 4bp, 5bp, and 6bp. For the screening of motif results, about 10% of EVs sRNAs are selected to contain the motif, and the FC value of EVs and leaf tissue sRNA is greater than 3. The probability of multiple nucleotides appearing at a certain position of some motifs is similar, and motifs with a probability of >60% of a nucleotide appearing at 2 / 3 of the entire motif are selected. These nucleotide motifs are named EXO motifs.

[0030] The present invention uses 21nt, 21-24nt, and 18-24nt sRNAs in EVs as target sequence data sets for HOMER motif identification, and 21nt, 21-24nt, and 18-24nt sRNAs in leaf tissues as background sequence data sets to identify nucleotide motifs enriched in EVs sRNAs. When the program searches for motifs, all reads of this length in the sequencing data set are used, and the abundance of each sRNA is retained, wherein the number of 21nt sRNAs in leaf tissues is 4.35-5.99 times that of EVs, the number of 21-24nt sRNAs in leaf tissues is 6.76-9.41 times that of EVs, and the number of 18-24nt sRNAs in leaf tissues is 3.49-4.53 times that of EVs.

[0031] The present invention lists the representative motifs identified ( Figure 1 In particular, the GGGUCC motifs identified in 21-24 nt sRNAs were present in 12.83% of EVs sRNAs and 0.10% of leaf sRNAs, and its enrichment in EVs was 135.05-fold higher than that in leaf tissues.

[0032] 2. EXO motifs control miRNA loading on plant EVs

[0033] The present invention utilizes the method of site-directed mutagenesis to introduce EXO motifs into or delete them from miRNA sequences. The two motifs CAUAG and GGGUCC were selected. In order to determine the position where the motifs were introduced, the present invention counted the main positions of the two motifs in 21nt sRNAs. The first nucleotide C of CAUAG mainly appears at the 3rd position of 21nt sRNAs, and the first nucleotide G of GGGUCC mainly appears at the 16th position of 21nt sRNAs.

[0034] nb-miR156I is a miRNA contained in EVs. It did not show specific enrichment in EVs. The first five nucleotides UGACA were mutated to CAUAG to introduce the CAUAG motif; the 16th A was converted to G, the 18th C was transposed to G, and the 19th A was transposed to U to introduce the GGGUCC motif. A mutant of nb-miR156I containing the CAUAG and GGGUCC motifs was constructed (e.g. Figure 2 ).

[0035] For N. benthamiana plants grown for 3-4 weeks, the present invention used Agrobacterium to transform the three edited nb-miR156I mutants mentioned above, collected EVs after 2.5 days, and quantified the relative content of miRNA in EVs and leaf tissues by stem-loop RT-PCR and QPCR. Figure 2 As shown in B, the introduction of CAUAG and GGGUCC into the miRNA sequence increased the ratio of the relative content of the modified miRNA in EVs and leaf tissues.

[0036] For nb-miR408a containing CCCUG, the present invention replaces it by two similar strategies (such as Figure 2 The result is shown in C. Figure 2 As shown in D, the relative content ratios of the modified nb-miR408a in EVs and leaf tissues decreased by 73 and 30 times, respectively.

[0037] 3. Plant EVs actively load amiRNA targeting c-myc

[0038] (1) The present invention designs five 21nt amiRNAs containing AACG, CAUAG, and GGGUCC motifs for mouse c-myc mRNA (NM_001177352), which are completely complementary to the c-myc mRNA sequence and reduce the possibility of off-target effects (e.g. Figure 3 A and B in the figure).

[0039] (2) The present invention uses the pRS300 plasmid (https: / / www.addgene.org / 22846 / ) (Plant Cell 2006 May;18(5):1121-33.) containing the hairpin structure sequence of Arabidopsis miR319a precursor as a template, and constructs a targeting c-myc by replacing the miR319a mature sequence and miR319a* sequence in the precursor. The precursor sequence of amiRNA and the replacement primer were designed by WMD (http: / / wmd3.weigelworld.org / ), and then the precursor sequence was inserted into the transient expression vector pGD-35S-tHSP to obtain the expression vectors pGD-35S-amiR-myc-GGGUCC-5'UTR-tHSP, pGD-35S-amiR-myc-CAUAG-ORF-2-tHSP, pGD-35S-amiR-myc-CAUAG-ORF-1-tHSP, pGD-35S-amiR-myc-AACG-ORF-tHSP and pGD-35S-amiR-myc-AACG-5'UTR-tHSP. The construction diagram is shown in Figure 4 shown.

[0040] (3) Inject Agrobacterium carrying the amiRNA expression vector into the leaves of 3-4 week-old Nicotiana benthamiana plants grown in the greenhouse. After 2.5 days, cut the leaves with scissors and wash them with clean water. Place the leaves on a tray covered with paper towels, gently wipe off the surface moisture with paper towels, stack the leaves into a pile, place them in a 300 mL beaker, and add 1×VIB buffer (20 mM MES, 2 mM CaCl 2, and 0.1M NaCl, pH=6.0) to cover the leaves, and take a clean bottle cap of appropriate size and place it on the liquid surface. Apply vacuum to allow the buffer to enter the intercellular spaces of the leaves, and extract 3 times, 7 minutes each time. After the leaves are completely soaked, use clean tweezers to pick up the leaves, lay them flat on a tray covered with paper towels, and gently wipe off the surface water with paper towels. Take 6 to 8 leaves and stack them on each other, with large leaves on the bottom layer and small leaves on the top layer. Gently roll it into a cylinder and put it in a special centrifuge tube. Use a desktop centrifuge (Thermo) F14-6×250LE carbon fiber angle rotor fixed angle rotor, 700g 4℃ for 20min. After centrifugation, aspirate the apoplast eluate with a pipette, divide it into 1.5mL Axygen EP tubes, and centrifuge it at 10,000g 4℃ for 30min. After centrifugation, the supernatant was slowly pipetted into another new 1.5 mL EP tube and filtered through a 0.45 μm microporous filter to remove larger vesicles. The filtered apoplast eluate was dispensed into 1.5 mL Axygen EP tubes and centrifuged at 40,000 g at 4 ° C for 3 h using a Beckman high-speed centrifuge JA-18.1 fixed angle rotor. After centrifugation, the supernatant was discarded and the precipitate was the Nicotiana benthamiana EVs.

[0041] The present invention detects their relative contents by stem-loop RT-PCR and QPCR, and the results are as follows Figure 3 As shown in Figure C, the relative expression levels of the five amiRNAs containing EXO motifs were significantly increased compared to the empty vector, indicating that these amiRNAs containing EXO motifs were effectively secreted into extracellular vesicles. Figure 3 As shown in D, amiR-myc-CAUAG-ORF-2 had the highest relative content in EVs, followed by amiR-myc-GGGUCC-5'UTR targeting the 5'UTR region of c-myc mRNA.

[0042] 4. Plant EVs loaded with amiR-myc inhibit tumors in vitro

[0043] (1) The present invention uses the number of EVs particles as the standard for dosing, and the number of particles is measured by dynamic light scattering (DLS). 0, 2.5×10 9 , 5×10 9 , 1×10 10 , 5×10 10 , 1×10 11 , 2.5×10 11EVs loaded with amiR-myc-CAUAG-ORF-2 or amiR-myc-GGGUCC-5'UTR were incubated for 48 h. CCK8 assay showed that EVs loaded with amiR-myc-GGGUCC-5'UTR had the best inhibitory effect on cancer cell proliferation. The results are shown in Figure 5 As shown in A, applying 1.655×1011 EVs achieved half inhibition, which indicates that EVs loaded with amiR-myc-GGGUCC-5'UTR have a significant inhibitory effect on cancer cell proliferation.

[0044] (2) The present invention further detected the effect of EVs loaded with amiR-myc-GGGUCC-5'UTR on the apoptosis of HCT116 and myeloma cells ARP1. Tumor cells in the logarithmic growth phase were collected and plated in 6-well plates at 250,000 cells per well. 2.5×10 11 EVs loaded with amiR-myc-GGGUCC-5'UTR were incubated with cells for 48 h. Figure 5 As shown in B and C, B shows that EVs loaded with amiR-myc-GGGUCC-5'UTR promoted apoptosis of HCT116 and ARP1 cells, showing a better pro-apoptotic effect on ARP1 cells. C shows that the application of the above number of EVs reduced the expression of c-myc protein in both cell lines.

[0045] 5. Plant EVs loaded with amiR-myc suppress tumors in vivo

[0046] In the present invention, ARP1 cells were injected into the NOD / SCID mouse subcutaneously to construct a xenograft tumor model. Each mouse in the experimental group was injected with 5×10 10 The control group of mice was injected with an equal dose of empty EVs without amiR-myc-GGGUCC-5'UTR.

[0047] After 4 weeks, the tumor tissue was removed and tested. Figure 6 The results shown in AC show that the tumor volume of the group injected with EVs loaded with amiR-myc-GGGUCC-5'UTR is significantly smaller than that of the group injected with empty EVs. The tumor volume growth curve in D also shows that EVs loaded with amiR-myc-GGGUCC-5'UTR can inhibit the growth rate of tumors.

[0048] Before killing the mice and taking the tumor tissue blocks, the present invention injected the above-mentioned dose of PKH26-labeled EVs loaded with amiR-myc-GGGUCC-5'UTR or empty EVs through the tail vein. After 3 hours, the tumor tissue blocks were taken out and quickly frozen and sectioned. The results were as follows: Figure 6 As shown in Figures E and F, the present invention observed that PKH26-labeled plant EVs can be localized in tumor tissues. The immunohistochemical results of tumor tissues showed that the expression of c-myc protein in tumor tissues of mice injected with EVs loaded with amiR-myc-GGGUCC-5'UTR was significantly lower than that of mice injected with empty EVs.

[0049] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. A method for loading plant extracellular vesicles with amiRNA, characterized in that: include: The amiRNA is modified and loaded into the plant extracellular vesicle after modification; The modification includes: editing the nucleotide sequence of the amiRNA by substitution or mutation so that the sequence contains at least one EXO motifs; The EXO motifs include: one or more of AACG, CAUAG or GGGUCC.

2. The method according to claim 1, characterized in that: The length of the nucleotide sequence of the amiRNA is 16 to 26 nt.

3. A plant extracellular vesicle, characterized in that: The plant extracellular vesicles are prepared by the method according to claim 1 or 2.

4. The plant extracellular vesicle according to claim 3, characterized in that The amiRNA in the plant extracellular vesicle is a complementary sequence of any fragment of c-myc mRNA before transformation; the nucleotide sequence of the c-myc mRNA includes: a nucleotide sequence as shown in SEQ ID NO.1 or SEQ ID NO.

2.

5. The plant extracellular vesicle according to claim 4, characterized in that After modification, the amiRNA in the plant extracellular vesicle includes any one or more nucleotide sequences shown in SEQ ID NO.3-7.

6. The plant extracellular vesicle according to any one of claims 3 to 5, characterized in that The plant is tobacco, preferably Nicotiana benthamiana.

7. Use of the plant extracellular vesicles according to any one of claims 3 to 6 in inhibiting tumors.

8. Use of the plant extracellular vesicle according to any one of claims 3 to 6 in the preparation of a drug for inhibiting tumors.

9. The use according to claim 7 or 8, characterized in that: The tumor inhibition includes any one or more of the following: i) reduce the expression level of c-myc protein; ii) inhibiting tumor growth; iii) Promote tumor cell apoptosis.